Telangana emerges as global life sciences hub

HYDERABAD: Telangana has gained recognition as an international hub in the life sciences sector, recording strong growth across life sciences, biotechnology, pharmaceuticals and medical technology between December 2023 and January 2026.
Global pharma majors anchor investments in Hyderabad
The state’s life sciences ecosystem has expanded rapidly as leading global pharmaceutical, biotech and healthcare companies chose Hyderabad as their investment base. Telangana Global Life Sciences is now evolving into a major global power centre, driven by integrated research, manufacturing and innovation capabilities.
Over the past two years, around 190 companies have committed to new or expansion investments in the state. These proposals account for memoranda of understanding worth about ₹73,360 crore and are expected to generate over one lakh direct and indirect jobs.
BioAsia meet prompts review of investment momentum
Ahead of the BioAsia conference scheduled in Hyderabad on February 17 and 18, the industries department has submitted a detailed status report to the state government. The report outlines month-wise investments, employment commitments and the progress of MoUs signed by companies in the sector.
“These investments have positioned Telangana as a key node on the global life sciences map. Beyond economic growth, they strengthen employment generation, healthcare innovation and global competitiveness,” the department said. Policy stability and a pro-industry government have played a central role in attracting large-scale investments, it added.
Genome Valley, Green Pharma City drive ecosystem
The department highlighted Telangana’s integrated ecosystem, where research and development, global capability centres and manufacturing coexist. Initiatives such as Genome Valley, Green Pharma City, single-window clearances and public-private partnership models have provided clarity and confidence to investors.
Companies from the US, Japan, Germany and France, including Fortune 500 firms, have shown sustained interest in Telangana, reflecting confidence in the state’s governance framework. Demand for high-skilled jobs has risen in areas such as artificial intelligence, cell and gene therapy, biologics and digital health. Several projects are currently at different stages of execution.
Major investments since December 2023
Green Pharma City: 10 pharma companies; ₹12,610 crore; 20,600 jobs
Green Pharma City: 17 companies; ₹10,705 crore; 22,290 jobs
Eli Lilly: ₹8,850 crore; 2,500 jobs
Sanofi: ₹3,600 crore; 2,600 jobs
Meiji Pharma: New R&D centre in Genome Valley; ₹3,600 crore; 100 jobs
Medtronic: ₹2,905 crore; 1,500 jobs
Laurus Labs–KRKA: ₹2,250 crore; 2,800 jobs
RX Propellant: ₹2,000 crore facility with global-standard R&D; 10,000 jobs
Aragen Life Sciences: R&D expansion; ₹2,000 crore; 1,500 jobs
BMS: ₹850 crore; over 1,500 jobs
Biopolis: Research campus over 10 lakh sq ft; ₹700 crore; 6,500 jobs
HCA Healthcare: ₹663 crore; 3,000 jobs
Corning–ACD: Pharma glass tube hub; ₹531 crore; 150 jobs
Vivant Pharma: ₹519 crore; 310 jobs
Medtronic: First IT centre outside the US; ₹498 crore; over 300 jobs
Takeda: Dengue vaccine manufacturing with annual capacity of 5 crore doses
Providence: Expansion; additional 3,000 jobs
AMN: New global capability centre; 3,000 jobs
Agilisium: Global AI centre; 2,000 jobs
Bharat Biotech: Cell and gene therapy, viral vector manufacturing
Crimson Research Park: Integrated R&D centre over 20 lakh sq ft
Johnson & Johnson: New global capability centre
Vasandor Animal Health: ₹300 crore; 180 jobs
Suzen Medicare: IV fluids manufacturing unit; ₹250 crore; 400 jobs
MSN Life Sciences: ₹161 crore; over 750 jobs
Eugia: Expansion with ₹157.66 crore; 500 jobs
1Bio (PPP model): 1.5 lakh sq ft plug-and-play labs; ₹150 crore; 500 jobs
Olympus: New R&D centre; 500 jobs
Thermo Fisher: Bioprocess design centre; ₹90 crore
Hetero Labs: Pharma unit expansion; ₹15 crore; 50 jobs

